TMCnet News
Epizyme to Present New Preclinical Data on Tazemetostat and Epigenetic Target Identification Efforts at AACR Annual MeetingCAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that new preclinical data on tazemetostat, Epizyme’s lead product candidate and first-in-class EZH2 inhibitor, along with other epigenetic target identification efforts, will be presented in poster sessions at the American Association for Cancer Research Annual Meeting 2017 taking place in Washington, D.C., April 1–5, 2017. “2017 continues to be a transformational year for Epizyme as we work to rewrite cancer treatment through novel epigenetic medicines,” said Rob Bazemore, CEO of Epizyme. “We look forward to sharing these new data on tazemetostat and our innovative approach to advancing our preclinical pipeline with the oncology community at AACR.” “As we evaluate these data, we are particularly encouraged by new research revealing the important role EZH2 plays in the proliferation of multiple myeloma, and preclinical activity of our first-in-class EZH2 inhibitor, tazemetostat, as both monotherapy and combination therapy in in vitro models of multiple myeloma,” said Richard Chesworth, DPhil, senior vice president of research at Epizyme. “These findings reinforce the potential for tazemetostat as a treatment option across multiple B-cell malignancies.” Multiple myeloma is a cancer arising from terminally differentiated B-cell lymphocyte plasmablasts. Mounting evidence suggests that EZH2 is an important regulator of B-cell differentiation and may play an important role in clinical B-cell malignancies. Consistent with this role, inhibition of EZH2 alone has shown potent anti-proliferative effects in in vitro and in vivo preclinical models of multiple myeloma. In a new study being presented at AACR, Epizyme evaluated the efficacy of tazemetostat, an EZH2 inhibitor, as monotherapy and in combination with standard of care agents in preclinical models of multiple myeloma. Tazemetostat selectively inhibited intracellular H3K27 methylation in multiple myeloma cell lines and elicited a robust anti-proliferative effect in 14-day assays. Synergistic activity was observed when tazemetostat was combined with commonly used multiple myeloma therapeutics (glucocorticoid receptor agonists and small molecule immune system modulators) when cells were treated with tazemetostat for seven days prior to the addition of the standard-of-care drugs. Based on these results, studies with selected therapeutic modalities were expanded into in vivo xenograft models to further evaluate monotherapy and combination activity of tazemetostat in multiple myeloma. Data will also be presented from preclinical studies demonstrating synergistic activity following the addition of tazemetostat to current small molecule treatments for alignant rhabdoid tumors and atypical teratoid rhabdoid tumors, both rare and aggressive forms of cancer with high unmet medical need, typically affecting pediatric patients. In addition, Epizyme will present data demonstrating that tazemetostat induces potent and selective apoptosis in SMARCA2 and SMARCA4-deficient ovarian cell lines, which confirms SCCOHT (small cell carcinoma of the ovary hypercalcemic type) is also sensitive to CRISPR-mediated EZH2 gene ablation. These findings support Epizyme’s ongoing Phase 2 trial of tazemetostat in solid tumors, and may support future clinical evaluation in other tumor types such as lung cancers. Details of the poster presentations are as follows: Date & Time: Sunday, April 2, 1:00 - 5:00 p.m. ET Date & Time: Monday, April 3, 8:00 a.m. - 12:00 p.m. ET Date & Time: Tuesday, April 4, 8:00 a.m. - 12:00 p.m. ET Date & Time: Wednesday, April 5, 8:00 a.m. - 12:00 p.m. ET About Epizyme, Inc. Cautionary Note on Forward-Looking Statements Contact: Monique Allaire, THRUST IR [email protected] (617) 895-9511 |